Considering the documented upregulation of ferroptosis in patients with IBD and the significant prediction of ALOX5 as a magnolin active site, we postulated that the therapeutic effects of magnolin might be attributed to its modulation of the ferroptosis through interaction with ALOX5. Here, ALOX5 is linked to inflammatory bowel disease.